Be at ease - the FDA and Innovations Pharmacuetica

Be at ease - the FDA and Innovations Pharmacueticals are in harmony.

Brilacidin was designated “FAST TRACK” by the FDA.
the following is stipulated by the FDA:
————
Fast Track designation must be requested by the drug company. The request can be initiated at any time during the drug development process. FDA will review the request and make a decision within sixty days based on whether the drug fills an unmet medical need in a serious condition.

Once a drug receives Fast Track designation, early and frequent communication between the FDA and a drug company is encouraged throughout the entire drug development and review process. The frequency of communication assures that questions and issues are resolved quickly, often leading to earlier drug approval and access by patients.
————-

So as any reasonable person can see. Mr Ehrlich , innovation pharmaceutical’s CEO has and is in communications as to what the FDA needs for drug approval. RP

Ronald A Phillips